Research programme: small molecule cardiovascular therapeutics - Gilead Sciences

Drug Profile

Research programme: small molecule cardiovascular therapeutics - Gilead Sciences

Latest Information Update: 14 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences; University of Texas Southwestern Medical Center
  • Developer Gilead Sciences; Novartis; University of Texas Southwestern Medical Center
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 14 Jul 2010 Discontinued - Preclinical for Heart failure in USA (unspecified route)
  • 18 Nov 2006 Myogen has been acquired by Gilead Sciences
  • 13 Jul 2006 Myogen and Novartis have extended their licensing agreement through October 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top